Corrigendum to "Exploring the benefits of alirocumab as lipid-lowering therapy in people with diabetes and very high cardiovascular risk" [Diabetes Res. Clin. Pract. 222 (2025) 112055]

Affiliations

¹ Department of Medicine, Section of Diabetes and Metabolic Diseases, University of Padua Metabolic Diseases Division, University Hospital of Padova, Padua, Italy. Electronic address: angelo.avogaro@unipd.it.
² Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
³ Diabetes Unit, Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy.
⁴ Department of Medical Sciences, Unit of Internal Medicine, IRCCS "Casa Sollievo della Sofferenza" San Giovanni Rotondo (FG), Italy.
⁵ Medical and Scientific Department, Sanofi S.r.l., Milan, Italy.

Free article

Published Erratum

Angelo Avogaro et al. Diabetes Res Clin Pract. 2025 Nov.

Free article

. 2025 Nov:229:112177.

doi: 10.1016/j.diabres.2025.112177. Epub 2025 Apr 18.

¹ Department of Medicine, Section of Diabetes and Metabolic Diseases, University of Padua Metabolic Diseases Division, University Hospital of Padova, Padua, Italy. Electronic address: angelo.avogaro@unipd.it.
² Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
³ Diabetes Unit, Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy.
⁴ Department of Medical Sciences, Unit of Internal Medicine, IRCCS "Casa Sollievo della Sofferenza" San Giovanni Rotondo (FG), Italy.
⁵ Medical and Scientific Department, Sanofi S.r.l., Milan, Italy.

No abstract available

Erratum for

Exploring the benefits of alirocumab as lipid-lowering therapy in people with diabetes and very high cardiovascular risk.
Avogaro A, Buzzetti R, Candido R, Cosmo S, Notarianni L, Consolo E, Luciano M. Avogaro A, et al. Diabetes Res Clin Pract. 2025 Apr;222:112055. doi: 10.1016/j.diabres.2025.112055. Epub 2025 Feb 26. Diabetes Res Clin Pract. 2025. PMID: 40020784 Review.